Skip to main
VCYT
VCYT logo

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 47%
Hold 7%
Sell 7%
Strong Sell 0%

Bulls say

Veracyte Inc. reported significant growth in genomic test volume, achieving 39,107 tests, which reflects a 25% increase from the previous quarter, supported by an impressive 45% jump in urology tests from the Decipher platform. The company saw a strong performance in adjusted EBITDA, with margins increasing by 690 basis points year-over-year, and testing revenue hitting $112.2 million, marking a 24% rise in the fourth quarter. Furthermore, the revenue from Bethesda V and VI nodules surged over 80% year-over-year, bolstered by increased adoption and a positive outlook on the company's new products, indicating sustained operational momentum and potential for continued financial improvement in 2025.

Bears say

Veracyte Inc. faces a challenging outlook primarily due to slowing revenue growth, which decelerated from 29% in 3Q24 to 21% in 4Q24, driven by underperformance in key products like Afirma and Decipher tests alongside declines in the Biopharma and Product segments. Additionally, the revenue per test has shown a slight decline, dipping approximately 1% from the previous year, raising concerns about the sustainability of revenue levels moving forward. The company also risks facing hurdles related to physician adoption of new diagnostic tests and potential delays in obtaining insurer coverage, which could further complicate financial prospects.

Veracyte (VCYT) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 47% recommend Buy, 7% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 15 analysts, Veracyte (VCYT) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.